We are live on ! Find out more
CERO

CERo Therapeutics
CERO

Delisted

CERO was delisted on the 30th of October, 2025.

Back to rankings

45 hedge funds and large institutions have $101M invested in CERo Therapeutics in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

0.02% less ownership

Funds ownership: 0.04% → 0.03% (-0.02%)

31% less funds holding

Funds holding: 65 → 45 (-20)

36% less capital invested

Capital invested by funds: $159M → $101M (-$58.1M)

67% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 30

Holders
45
Holders Change
-20
Holders Change %
-30.77%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
7
Reduced
7
Closed
30
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Beryl Capital Management
California
+$5.52M
2
CC
Centiva Capital
New York
+$2.32M
3
WCMNY
Westchester Capital Management (New York)
New York
+$1.53M
4
DCM
Difesa Capital Management
New York
+$1.28M
5
ETH
Exos TFP Holdings
New York
+$1.28M

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$11M
2
Marshall Wace
Marshall Wace
United Kingdom
-$8.58M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$7.55M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$6.62M
5
WAM
Wolverine Asset Management
Illinois
-$4.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
51
Context Capital Management
California
– -$4.04M -200 Closed
MF
52
Magnetar Financial
Illinois
– -$3.64M -180 Closed
CSS
53
Cubist Systematic Strategies
Connecticut
– -$2.72M -135 Closed
CH
54
CVI Holdings
Delaware
– -$2.09M -103 Closed
WAM
55
Weiss Asset Management
Massachusetts
– -$2.07M -103 Closed
ACM
56
Atalaya Capital Management
New York
– -$2.02M -100 Closed
UOC
57
UBS O'Connor
Illinois
– -$1.93M -95 Closed
Hudson Bay Capital Management
58
Hudson Bay Capital Management
Connecticut
– -$1.78M -88 Closed
SOA
59
Sea Otter Advisors
Florida
– -$1.26M -62 Closed
JP Morgan Chase
60
JP Morgan Chase
New York
– -$1.01M -50 Closed
SSA
61
Schonfeld Strategic Advisors
New York
– -$1M -50 Closed
BCM
62
Basso Capital Management
Connecticut
– -$756K -37 Closed
RCM
63
Rivernorth Capital Management
Florida
– -$505K -25 Closed
WA
64
Whitebox Advisors
Minnesota
– -$505K -25 Closed
Parallax Volatility Advisers
65
Parallax Volatility Advisers
California
– -$340K -17 Closed
Bank of Montreal
66
Bank of Montreal
Ontario, Canada
– -$322 -16 Closed
LA
67
Linden Advisors
New York
– -$325K -16 Closed
VF
68
Virtu Financial
New York
– -$314K -16 Closed
SC
69
Sculptor Capital
New York
– -$296K -15 Closed
Verition Fund Management
70
Verition Fund Management
Connecticut
– -$264K -13 Closed
SV
71
Starboard Value
New York
– -$215K -11 Closed
HF
72
HRT Financial
New York
– -$138K -7 Closed
GCL
73
Glazer Capital LLC
New York
– -$103K -5 Closed
OMC
74
Old Mission Capital
Illinois
– -$106K -5 Closed
SCM
75
Segantii Capital Management
Hong Kong
– -$101K -5 Closed
1 2
3

CERO Hedge Fund Activity: Q4 2022 in Review

45 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q4 2022, worth a combined $101M — down 36% from $159M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of CERO and 10 opened new positions — a net loss of 20 holders — while 7 trimmed existing stakes and 7 added.

The largest buyer was Beryl Capital Management, opening a new position worth an estimated $5.52M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $11M sold.

  • 45 institutional investors held CERo Therapeutics (CERO) as of Q4 2022, down from 65 in Q3 2022.
  • Funds reported $101M of CERo Therapeutics stock for Q4 2022, down 36% quarter-over-quarter.
  • 10 funds opened new CERo Therapeutics positions in Q4 2022 and 30 closed out, a net change of -20 holders.
  • The largest CERo Therapeutics buyer in Q4 2022 was Beryl Capital Management, an estimated $5.52M added.
  • The largest CERo Therapeutics seller in Q4 2022 was Highbridge Capital Management, an estimated $11M sold.

Based on aggregated 13F filings for Q4 2022.